



## Expedeon AG announces outcome of Annual General Meeting 2019

*Shareholders approve all management proposals*

**Heidelberg, Germany and Cambridge, UK, 10 July 2018** – Expedeon AG (Frankfurt: EXN; ISIN: DE000A1RFM03; Prime Standard) today announced that the Annual General Meeting (AGM) held in Heidelberg yesterday, July 09, 2019, approved all management proposals. The participating shareholders represented 37.44% of the total share capital of about 51.56 million shares; all proposals were carried with a minimum Yes vote of 95.2% of the votes present.

“With a first-ever positive EBITDA, 2018 was the most successful year in Expedeon’s history to date. Our Q1 results confirmed the positive trend. Fundamental to this progress has been the acquisition strategy over the last years, through which we have built an exciting technology platform underpinning our ongoing R&D activities. Based on a pipeline full of innovative products, our primary focus is now on organic growth and building added value for our customers, investors, and shareholders alike,” **said Dr. Heikki Lanckriet, CEO of Expedeon.** “Our goal is translating this progress into long-term sustainable success. The strong support at yesterday’s Annual General Meeting gives us great confidence looking forward to the coming months and years, reaffirming that we are on the right track for the remainder of 2019 and the years to come.”

The AGM approved the discharge of the members of the Supervisory Board and the Management Board for fiscal year 2018 and the appointment of Ernst & Young, Mannheim, Germany as auditors for the fiscal year 2019.

Also, the AGM approved the authorization of the stock option plan 2019, as well as the establishment of a new contingent capital (Contingent Capital 2019) in order to fulfill the stock option plan 2019.

Mr. Hansjörg Plaggemars was elected as a new member of the supervisory board by the AGM. Mr. Plaggemars will follow Dr. Cristina Garmendia Mendizábal who had stepped down as chair and resigned from the supervisory board in April 2019. In its constituent assembly after the AGM, the supervisory board elected Mr. Joseph Fernandez as its new chair. Expedeon’s supervisory board consists of six members: Mr. Joseph Fernandez (Chairman), Mrs. Pilar de la Huerta, Dr. Trevor Jarman, Mr. Peter Llewellyn-Davies (Audit Committee Chair), Mr. Tim McCarthy, and Mr. Hansjörg Plaggemars.

Moreover, the AGM approved the transition of bearer shares into registered shares as well as the corresponding changes to the statutes and other alignments.

Furthermore, the AGM resolved the capital increase out of company funds by partially transforming the capital reserve into original capital according to §§ 207 ff. AktG and the subsequent reduction of the increased original capital for the purpose of the termination of the nascent amount in the capital reserve fund according to § 272 Abs. 2 r. 4 HGB subject to the regulations of the statutory capital decrease according to §§ 222 ff. AktG.

The AGM voting results for each agenda item will be published today in the [Investors section of Expedeon AG website](#).

**For further information, please contact:**

**Expedeon AG**

Dr. Heikki Lanckriet

CEO

Phone: +44 1223 873 364

Email: [heikki.lanckriet@expedeon.com](mailto:heikki.lanckriet@expedeon.com)

Investor website: [www.investors.expedeon.com](http://www.investors.expedeon.com)

**MC Services AG (Investor Relations and International Media Relations)**

Raimund Gabriel

Managing Partner

Phone: +49 89 210228 0

Email: [expedeon@mc-services.eu](mailto:expedeon@mc-services.eu)

**About Expedeon AG: [www.expedeon.com](http://www.expedeon.com)**

Expedeon is an enabler of exciting advances in medical science and patient care. The Company's core technologies, innovative products and services are used in research laboratories around the world, enabling scientists to push the boundaries of research and product development, and play an integral part in new diagnostic tools being brought to market. With applications spanning the entire workflows in genomics, proteomics and immunology, Expedeon's technologies both accelerate and simplify research and make new and cost-effective processes available to biopharmaceutical and diagnostic organisations alike, thereby underpinning its customers' development and commercialisation objectives. Expedeon's products are sold through a direct sales force and several distribution partners in Europe, the USA and Asia. Expedeon AG has offices in Germany, Spain, UK, USA and Singapore. The Company is listed on the Prime Standard segment of the Frankfurt Stock Exchange (Ticker: EXN; ISIN: DE000A1RFM03).

### This publication is intended for information only and constitutes neither an offer to sell nor an invitation to buy securities. Some statements included in this press release, relating neither to proven financial results nor other historical data, should be viewed as forward-looking, i.e. not definite. Such statements are mainly predictions of future results, trends, plans or goals. These statements should not be considered to be total guarantees since given their very nature they are subject to known and unknown risks and imponderability and can be affected by other factors as a consequence of which the actual results, plans and goals of Expedeon AG may deviate greatly from the established conclusions or implied predictions contained in such statements. Expedeon does not undertake to publicly update or revise these statements in the light of new information or future results or for any other reason. ###